Is there a difference in testosterone levels and its regulators in men carrying BRCA mutations?
PDF | HTML | How to cite
Metrics: PDF 1121 views | HTML 1874 views | ?
Hanan Goldberg1, Liat Shavit Grievink1, Roy Mano1, Yaara Ber1, Rachely Ozalbo1, Sivan Tuval1, Jack Baniel1 and David Margel1
1Division of Urology, Rabin Medical Center, Petah Tikva and The Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Hanan Goldberg, email: [email protected]
Keywords: BRCA mutations, free androgen index, luteinizing hormone, prostate cancer, testosterone
Received: February 03, 2017 Accepted: September 16, 2017 Published: October 10, 2017
Background: Male BRCA mutation carriers are at risk for an early onset aggressive prostate cancer. No data exist on the association of testosterone levels among these patients. We aimed to analyze testosterone and associated hormonal levels among male BRCA carriers and non-carriers.
Patients and methods: Overall 87 male carriers and 43 non-carriers aged 40-70 were prospectively enrolled. Clinical data were collected and all patients were tested for total testosterone (TT), prostate specific antigen (PSA), follicle stimulating hormone (FSH), luteinizing hormone (LH), free androgen index (FAI), sex hormone binding globulin (SHBG) and prolactin. Multivariate linear regression analysis was performed to predict TT levels.
Results: The median age, mean BMI, comorbidities, PSA, FSH, LH and SHBG levels in both groups were similar. However, mean TT and FAI were higher in the carriers (16.7 nmol/l vs 13.5 nmol/l, p=0.03 and 39.5 vs 34.8, p=0.05, respectively), while prolactin was significantly lower. Multivariate analysis demonstrated that while BMI was inversely correlated to TT levels in both groups, LH was a predictor only in non-carriers.
Conclusions: Carriers have higher TT and FAI levels and lower prolactin levels; but LH does not predict their TT levels. Further research in a larger cohort of BRCA carriers with and without prostate cancer should be performed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.